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Abstract  Systemic  inﬂammation  has  been  implicated  in  the  pathogenesis  of  chronic  obstruc-
tive pulmonary  disease  (COPD)  systemic  effects.  However,  most  COPD  patients  do  not  suffer
from persistent  systemic  inﬂammation  even  after  exacerbations  and  exercise  and  scientiﬁc  evi-
dence has  provided  conﬂicting  results.  Our  aim  is  to  evaluate  inﬂammatory  gene  expression  at
rest and  at  1  and  24  h  after  strenuous  exercise  in  COPD  patients  and  study  the  patient  variables
associated with  inﬂammatory  expression.
A cross-sectional  study  was  conducted  in  COPD  patients  who  were  recruited  on  entry  to
a pulmonary  rehabilitation  (PR)  program.  Demographic,  clinical  and  functional  data  were  col-
lected. Blood  samples  were  collected  and  gene  expression  was  analyzed  by  reverse  transcriptase
polymerase  chain  reaction  for  IFNg,  IL1b,  IL6,  IL8,  TNFa,  TGFb1  and  iNOS.
The study  included  21  patients  (15  men,  71.4%),  mean  age  66.1  years  old  (SD  =  8.27),  mean
FEV1 46.76%  (SD  20.90%),  67%  belonging  to  GOLD  grade  D,  mean  BODE  index  of  3.9,  90.5%  with
smoking history,  mean  BMI  25.81  (SD  =  4.87),  median  of  1.29  exacerbations  in  the  previous  year.
There was  no  statistical  signiﬁcant  difference  between  inﬂammatory  expression  at  rest  and
at 1  h  and  24  h  after  the  maximal  exercise  test  for  all  tested  genes.
We found  an  association  between  BMI  and  inﬂammatory  expression  at  all  the  points  of  time
checked,  a  slight  inverse  association  occurs  with  low  BMI  for  mRNA  IL1b,  IL6,  TNFa,  TGFb1  and
iNOS, and  there  was  a  more  pronounced  positive  association  for  obese  patients  for  all  tested
genes.
This preliminary  study  did  not  show  an  enhanced  inﬂammatory  gene  expression  from  rest  to
1 h  and  24  h  after  short-term  exercise,  but  did  show  an  increased  inﬂammatory  gene  expression Study was carried out at the Pulmonary Rehabilitation Unit, Pneumology Service, CHLN-Hospital Pulido Valente and in South Luso-
Transplant Centre.
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in  both  BMI  extremes,  both  at  rest  and  after  exercise,  suggesting  not  only  malnourishment,  but
also obesity  as  potential  links  between  COPD  and  systemic  inﬂammation.  Studies  with  larger
samples and  designed  to  deﬁnitely  exclude  OSA  or  OHS  as  confounding  factors  in  obese  patients
are required.
©  2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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hronic  obstructive  pulmonary  disease  (COPD)  is  associated
ith  important  extrapulmonary  manifestations,  including
eight  loss,  skeletal  muscle  dysfunction,  cardiovascular  dis-
ase,  depression,  osteoporosis,  reduced  exercise  tolerance,
nd  poor  health  status.1--3 Although  the  pathobiology  of
OPD  has  not  been  fully  determined,  persistent  systemic
nﬂammation  has  been  implicated  in  the  pathogenesis  of
he  majority  of  these  systemic  effects.3,4 Elevated  circu-
ating  levels  of  white  blood  cells,  C-reactive  protein  (CRP),
nterleukins  6  (IL-6)  and  8  (IL-8),  ﬁbrinogen  and  tumor  necro-
is  factor  alpha  (TNFa)  have  been  reported  in  patients  with
OPD.5 However,  the  ECLIPSE  study5 has  demonstrated  that
 large  group  of  patients  with  COPD  do  not  suffer  from  sys-
emic  inﬂammation.
The  role  of  exercise  in  COPD  inﬂammatory  process  has
lso  been  a  matter  of  debate.6--15 Patients  with  COPD
re  exposed  to  a  systemic  inﬂammation  that  is  ampliﬁed
y  exhaustive  exercise.  Inﬂammatory  response  to  exer-
ise  is  more  pronounced  in  patients  with  COPD  when
ompared  to  healthy  controls,  even  at  lower  levels  of
xercise  intensity.9,15 However,  scientiﬁc  literature  on  this
ubject  is  also  not  consensual,  as  several  studies  have
hown  a  reduction  in  the  level  of  TNFa  protein  expres-
ion  in  COPD  subjects.10 As  pointed  out  by  Canavan  and
olleagues,11 some  of  the  heterogeneity  of  these  results
ight  be  caused  by  the  different  methods  that  were  used
n  the  studies  (patient  characterization,  exercise  proto-
ols,  and  assay  techniques).  Crul  and  colleagues12 did  not
nd  any  evidence  of  muscle  inﬂammation  in  patients  with
OPD,  independently  of  whether  they  were  in  a  stable  or
n  acute  exacerbation  state.  Conversely,  others  have  sug-
ested  an  anti-inﬂammatory  effect  of  regular  exercise  in
ome  low  systemic  inﬂammation  chronic  diseases,  with  ben-
ﬁcial  outcomes  in  disease  prevention  and  symptomatic
mprovement.6,13,14
In  this  study  we  aim  to  evaluate  the  inﬂammatory  and
mmune  regulatory  gene  expression  proﬁling  in  peripheral
lood  determined  at  rest  in  patients  with  COPD,  and  the
ossible  modiﬁcation  after  strenuous  exercise,  and  search
or  variables  and  patients’  characteristics  associated  with
nﬂammatory  expression.
aterial and methodsatients
 cross-sectional  study  was  conducted  on  a  sample  of  21
atients  diagnosed  with  COPD,  according  to  the  Global
A
a
hnitiative  for  Obstructive  Lung  Disease  Project  (GOLD)16 as
ost  bronchodilator  FEV1/FVC  <  0.70.  Patients  were  consecu-
ively  recruited  on  entry  to  a  pulmonary  rehabilitation  (PR)
rogram  at  our  PR  Unit,  from  January  to  December  2010.
articipants  were  selected  if  clinically  stable  in  the  previ-
us  four  weeks  and  able  to  exercise  and  to  answer  health
tatus  questionnaires.  Patients  diagnosed  with  other  signif-
cant  lung  diseases,  e.g.  asthma,  bronchiectasis  or  other
onditions  that  might  cause  dyspnea  or  affect  exercise  per-
ormance,  were  excluded.
ata  collection
ata  collection  included  age,  body  mass  index  (BMI),  smok-
ng  history,  number  of  exacerbations  in  the  previous  year  and
omorbidities.  Clinical  data  were  obtained  by  interview  and
rom  medical  records,  including  the  review  of  concomitant
edications.  Charlson,17 Charlson-age18 and  COTE  (COPD
peciﬁc  comorbidity  test)19 indexes  were  calculated  based
n  comorbidities  data.  Participants  completed  question-
aires  on  dyspnea  (modiﬁed  Research  Council  breathlessness
cale  and  Mahler’  baseline  dyspnea  index),20 activities  of
aily  living  (London  Chest  Activity  of  Daily  Living  scale
- LCADL),21 anxiety  and  depression  (Hospital  Anxiety  and
epression  scale  --  HADS),22 and  health  status  (St.  George’s
espiratory  Questionnaire  --  SGRQ).23
Pulmonary  function  data  were  obtained  using  standard-
zed  equipment  (SensorMedics  Corporation,  Yorba  Linda,
A,  USA).  Post-bronchodilator  spirometric  values  were
btained.  Data  were  measured  as  absolute  values  (L)  and
s  percent  predicted  of  reference  values.
xercise  test  and  laboratory  procedures
atients  were  subjected  to  an  incremental  exercise  test  to
aximum  tolerated  on  a  treadmill  or  on  a  cycle  ergome-
er  (Fig.  1).  Treadmill  protocol  started  with  a  three  minutes
arming  up  at  2.0  km/h  and  0◦ inclination,  followed  by
.5  km/h  increments  per  minute  and  0◦ inclination  until  the
atient  attained  a  brisk  walking  speed  without  running,  and
hen  increments  of  2◦ inclination  every  minute  until  exhaus-
ion.  Cycle  ergometer  protocol  starts  with  a  three  minutes
arm  up  with  no  added  resistance,  followed  by  10  W  of
ncrements  each  minute  until  exhaustion.  Safety  criteria
or  terminating  the  exercise  test  were  applied  according  to
TS/ACCP  guidelines.24
Whole  blood  samples  were  collected  from  each  patient
t  three  different  time  points:  at  rest  (T0),  and  at  one
our  (T1)  and  24  h  (T2)  after  the  exercise  test.  Additionally,
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wFigure  1  Blood  sampling  sc
a  blood  sample  from  the  ﬁrst  ten  patients  entering  the  study
was  collected  the  day  before  (C0),  and  considered  as  a
calibration  sample  for  relative  gene  expression  analysis  to
establish  the  expression  pattern  of  target  genes  in  resting
condition.  These  participants  were  told  to  maintain  normal
low-intensity  activities  of  daily  living  and  avoid  exercising
above  that  intensity  in  the  previous  48  h.
RNA  integrity  from  blood  cells  was  immediately  pre-
served  at  collection  with  the  PAXgene  Blood  RNA  Tubes
(PreAnalytiX  GmbH,  Hombrechtikon,  Switzerland).  Each
sample  tube  was  kept  at  room  temperature  for  2  h,
followed  by  incubation  at  −20 ◦C  for  24  h  and  there-
after  stored  at  −80 ◦C.  Thawed  tubes  were  processed
with  the  PAXgene  Blood  RNA  Kit  (PreAnalytiX  GmbH)
for  isolation  of  total  RNA  according  to  manufacturers’
instructions,  including  DNAse  digestion.  Yield  of  puri-
ﬁed  RNA  samples  was  evaluated  with  a  NanoDrop  2000
spectrophotometer  (Thermo  Fisher  Scientiﬁc,  Wilmington,
USA)  and  stored  at  −80 ◦C.  Gene  expression  was  ana-
lyzed  by  reverse  transcriptase  polymerase  chain  reaction
(RT-PCR),  essentially  as  previously  described.25 Brieﬂy,  a
template  cDNA  was  generated  by  reverse  transcription
from  1  to  2  g  of  total  RNA  using  the  High  Capacity  cDNA
Archive  Kit  (Applied  Biosystems,  Foster  City,  CA).  Mea-
surements  of  target  genes  and  endogenous  control  (beta
actin)  were  performed  using  the  Taqman  Gene  Expres-
sions  Assays  in  combination  with  TaqMan  Fast  Advanced
Mastermix  on  a  7900  HT  system  (Applied  Biosystems),
according  to  manufacturers’  instructions.  The  analyzed
genes  and  each  primer/probe  assay  ID  were  the  following:
interleukin  1  beta  (IL-1, Hs00174097  m1),  interleukin  6  (IL-
6,  Hs00174131  m1),  interleukin  8  (IL-8,  Hs00174103  m1),
inducible  nitric  oxide  synthase  (iNOS,  Hs00167248  m1),
interferon  gamma  (IFN-, Hs00174143  m1),  tumor  necrosis
factor  (TNF-, Hs00174128  m1),  transforming  growth  factor
beta  1  (TGF-1, Hs00998133  m1).  The  efﬁciency  for  each
primer/probe  assay  was  above  95%  (as  determined  by  the
manufacturer).
Endogenous  gene  expression  was  used  for  each  assay
normalization  and  gene  expression  was  calculated  by  the
adapted  formula  2−DCt*1000,  which  infers  the  number  of
mRNA  molecules  of  the  gene  of  interest  per  1000  molecules
of  the  endogenous  controls.26 DCt  stands  for  the  difference
between  the  cycle  threshold  of  the  target  gene  and  that  of
the  endogenous  control  genes.
A week  after  the  maximum  exercise  test,  patients
performed  a  6-minute  walking  test  (6MWT),  standard-
ized  according  to  international  guidelines.27 6MW  distance,
FEV1%  predicted  after  bronchodilator,  mMRC  dyspnea  scale
and  BMI  data  were  aggregated  to  calculate  BODE  index.28
Subjects  were  willing  and  able  to  participate  in
this  study  and  gave  written  informed  consent  prior  to
(
t
( and  maximal  exercise  test.
aseline  measurements.  The  hospital’s  Ethics  committee
nd  administration  board  approved  the  trial  (IRB:  Study
5/07 CE/027/07),  and  all  data  were  processed  anony-
ously  according  to  the  institution’s  privacy  policy.
tatistical  analysis
ategorical  data  were  presented  as  frequencies  and  per-
entages,  and  continuous  variables  as  mean  or  median,  SD  or
nterquartile  range:  25th  percentile  (P25)  to  75th  percentile
P75).  To  verify  the  normality  assumption  of  parametric
ests,  Shapiro--Wilk  goodness-of-ﬁt  test  and  Q--Q  plots  were
sed.  To  compare  genetic  inﬂammatory  markers  between
0  and  C0,  T0  and  T1,  and  T0  and  T2,  nonparametric  tests
ere  used  (exact  Wilcoxon  signed  ranks  test  or  sign  test
hen  the  differences  had  no  symmetric  distributions).  To
dentify  associations  between  patients’  characteristics  and
enetic  inﬂammatory  expression  in  all  time  points,  LOWESS
Locally  Weighted  Scatterplot  Smoother),  Spearman’s  cor-
elation  coefﬁcient  and  Mann--Whitney  test  were  applied.
he  signiﬁcance  level  ˛  =  0.05  was  considered.  Due  to  the
xploratory  nature  of  the  study,  no  multiple  testing  proce-
ures  were  used.
All  data  were  analyzed  using  the  Statistical  Package  for
he  Social  Sciences  for  Windows  21.0  (IBM  Corp.  Released
012.  IBM  SPSS  Statistics  for  Windows,  Version  21.0.  Armonk,
Y:  IBM  Corp.).
esults
 total  of  21  patients  were  recruited,  agreed  to  participate
nd  entered  the  study.  There  were  no  dropouts.  Participants
ample  included  15  men  (71.4%),  with  a  mean  age  of  66.1
ears  (SD  =  8.27),  19  (90.5%)  with  smoking  history  (16  previ-
us  smokers  --  76.2%  and  3  active  smokers  --  14.3%),  with  an
verage  69  pack-years  (range  12--150)  and  2  never  smokers
9.5%).  These  latter  patients  were  in  fact  never  smokers  with
 long-term  second-hand  smoke  exposure.  One  woman  was
xposed  for  years  to  her  husband  smoking  at  home,  and  the
ther  woman  was  also  exposed  for  years  to  her  family  smok-
ng  at  home  and  to  her  colleagues  smoking  at  work.  Fourteen
atients  (66.6%)  had  respiratory  failure,  54.1%  hypoxemic
nd  9.5%  hypercapnic.
According  to  GOLD  categories,16 14  (67%)  patients
elonged  to  category  D.  Mean  FEV1 was  46.76%
SD  =  20.90%,  min  21%,  max  97%  predicted),  median  BODE
as  3.9  (min  0,  max  8)  and  a  median  of  1.3  exacerbations
min  0,  max  10)  had  occurred  in  the  previous  year.
Mean  BMI  were  25.81  kg  m−2 (SD  =  4.9),  ranging  from  17
o  34  kg  m−2.  Three  participants  (14%)  were  malnourished,  8
38%)  were  overweight,  and  four  patients  (19%)  were  obese
3 F.  Rodrigues  et  al.
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Table  1  Baseline  characteristics  of  COPD  participants.
Spirometry  values  displayed  are  post-bronchodilator.
Demographics
Gender  m/wn  (%) 15  (71.4%)/6  (28.6%)
Ageyears  mean  (SD)  min--max 66.05  (8.27)  50--82
BMIkg.m−2 mean  (SD)  min−max 25.81  (4.87)  17--34
Pack’smean  (SD)  min--max 69.05  (30.85)  12--150
Symptoms/health  status
mMRCmedian  (min--max) 1.00  (0--3)
Mahler’s  BDImedian  (min--max) 7.00  (3--10)
LCADLmedian  (min--max) 19.15  (8--36)
HADS-anxietymedian  (min--max) 6.19  (1--14)
HADS-depressionmedian  (min--max) 5.62  (0--12)
SGRQmedian  (min--max) 45.95  (27--77)
BODEmedian  (min--max) 3.90  (0--8)
Exacerbations  previous
yearmedian  (min--max)
1.29  (0--10)
GOLD  categories  A/B/C/Dn  (%) 2  (9.5)/2  (9.5)/3
(14.3)/14  (66.6)
Comorbidities
COTEmedian  (min--max) 1.24  (0--8)
Charlsonmedian  (min--max) 1.62  (1--3)
Charlson-agemedian  (min--max) 3.57  (2--5)
Respiratory  failure/hypoxemic/
hypercapnicn  (%)
14  (66.6)/12  (54.1)/2
(9.5)
Cardiovascular  comorbiditiesn  (%) 15  (71.4)
Arterial  hypertensionn  (%) 11  (52.4)
Congestive  heart  failure/Cor
pulmonalen  (%)
5  (23.8)
Ischemic  heart  diseasen  (%) 2  (9.5)
Arrythmiasn  (%) 2  (9.5)
Tuberculous  sequelaen  (%) 7  (33.3)
Bronchiectasisn  (%) 2  (9.5)
Obesity  or  overweightn  (%) 12  (57.1)
Malnourishedn  (%) 3  (14.3)
Diabetes  mellitusn  (%) 1  (4.8)
Dyslipidemian  (%) 4  (19.0)
Osteoarticular  pathologyn  (%) 4  (19.0)
Physiology
FVCL  mean  (SD)  min--max 2.75  (0.95)  0.84--5.31
FVC%mean  (SD)  min--max 85.52  (23.74)  32--139
FEV1 L  median  (P25-P75)  min--max 1.02  (0.73--1.46)
0.47--3.25
FEV1%  mean  (SD)  min--max 46.76  (20.90)  21--97
FEV1/FVC%  mean  (SD)  min--max 43.48  (14.11)  21--69
TLCL  (n  =  19)  mean  (SD)  min--max 7.11  (1.37)  4.14--8.71
TLC%  (n  =  19)  mean  (SD)  min--max 121.53  (15.64)
86--155
RVL  (n  =  19)  mean  (SD)  min--max 4.26  (1.27)  2.51--6.43
RV%  (n  =  19)  mean  (SD)  min--max 189.79  (49.19)
128--293
DLCO%  (n  =  17)  mean  (SD)  min--max 45.12  (19.07)  16--95
KCO%  (n  =  17)  mean  (SD)  min--max 41.41  (17.49)  13--76
PaO2  mmHg  mean  (SD)  min--max 65.46  (8.58)  50--77
PaCO2  mmHg  median  (P25-P75)  min--max 42.10  (37.20--46.05)
35--60
6MWDm  mean  (SD)  min--max 346.05  (86.06)18  
BMI  30--34  kg  m−2).  Of  these  latter,  one  had  mild  obstructive
leep  apnea  (OSA)  with  an  Apnea  Hypopnoea  Index  (AHI)  of
.1  events/hour,  and  the  other  had  moderate  obstructive
leep  apnea  with  an  Apnea  Hypopnea  Index  (AHI)  of  25.7
vents/hour.  Neither  of  these  two  patients  were  on  CPAP  at
he  time  of  the  study.  In  the  other  two  obese  patients,  OSA  or
ypoventilation  were  excluded  based  on  the  absence  of  typ-
cal  night  and  daytime  complaints,  on  physical  examination
nd  on  normal  arterial  blood  gases.
In  relation  to  respiratory  comorbidities,  tuberculous
equelae  diagnosis  (n  =  7)  were  made  according  to  a  history
f  past  pulmonary  tuberculosis  and  imagiologic  features  such
s  calciﬁed  granuloma,  focal  ﬁbrosis  or  localized  pleural
hickening.  None  of  these  radiologic  features  were  cur-
ently  considered  as  clinically  relevant.  Similarly,  cylindrical
ronchiectasis  was  found  in  two  patients,  and  interpreted  as
ssociated  with  COPD.
The  most  prevalent  comorbidities  in  our  sample  were
ardiovascular  (CV)  disease,  arterial  hypertension  being  the
ost  common  (52.4%).
Both  patients  with  and  without  cardiovascular  comorbidi-
ies  exercised  on  the  same  ergometers  (cycle  and  treadmill)
nd  used  the  same  protocols:  of  15  patients  with  cardiovas-
ular  comorbidity,  5  exercised  on  cycle  ergometer  and  10  on
readmill.  Of  6  patients  without  cardiovascular  comorbidity,
 exercised  on  cycle  ergometer  and  3  on  treadmill.
Patients  without  cardiovascular  comorbidity  achieved
igher  work  load  on  cycle  ergometer  [mean  (SD):  83  (22)  W,
in--max:  70--108  W  versus  mean  (SD):  58  (25)  W,  min--max:
0--100  W]  but  lower  workload  on  the  treadmill  [mean  (SD):
 (0.76)  km/h  and  7  (6.93)◦ inclination,  min--max:  4.5  km/h,
.2◦ --  6  km/h,  12◦ versus  mean  (SD)  5  (0.96)  km/h  and
0◦ (7.44),  min--max:  4.0  km/h,  0◦ --  6  km/h,  22◦].  All  the
atients  exercised  to  their  maximal  tolerance.
Cardiopulmonary  exercise  tests  data  are  shown  in  Annex,
able  1a.
Mean  6MWD  was  346.1  meters  (SD  =  86.1),  ranging  from
85  to  520  meters.  Oximetry  lowest  values  at  6-minute  walk-
ng  test  were  on  average  85%,  ranging  from  68%  to  94%.
aseline  characteristics  are  presented  in  Table  1.
Pharmacological  treatment  was  as  follows:  18  partici-
ants  were  on  triple  therapy  with  long-acting  muscarinic
ntagonist  (LAMA)  Tiotropium,  long-acting  beta-adrenergic
LABA)  Salmeterol  or  Formoterol  and  inhaled  corticosteroid
ICS)  Budesonide,  Beclometasone  or  Fluticasone;  2  partic-
pants  were  on  LABA  and  ICS,  one  was  on  LABA,  ICS  and
hort  acting  muscarinic  antagonist  (SAMA)  Ipratropium  and
ne  participant  was  on  rescue  short  acting  beta-adrenergic
SABA)  Salbutamol,  and  Acetylcystein.  Eight  patients  were
n  Theophylline,  4  were  on  statins  (Simvastatin,  Atorvas-
atin  or  Rosuvastatin)  and  2  were  on  Amiodarone.
Seven  patients  were  on  long-term  oxygen  therapy  (LTOT)
nd  one  was  on  LTOT  and  non-invasive  ventilation  (NIV).  One
ormal-weight  patient  was  on  CPAP  due  to  obstructive  sleep
pnea.
The  pharmacological  therapy  used  by  the  four  obese
atients  and  the  other  participants  was  essentially  the  same:
hree  were  on  triple  therapy  LAMA,  LABA  and  ICS,  one  was
n  LABA  and  ICS.  Three  were  on  theophylline  and  2  were  on
tatins.  None  of  the  patients  were  on  oral  corticosteroids  or
oﬂumilast.  None  of  the  four  patients  were  on  LTOT,  NIV  or
PAP.
185--520
6MWD%pred  mean  (SD)  min--max 61.00  (19.50)  29--102
6MWT SpO2%  mean  (SD)  min--max 84.57  (6.67)  68--94
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Table  2  Median  (P25--P75)  of  the  mRNA  inﬂammatory  genes  at  rest  (T0),  and  at  1  h  (T1)  and  24  h  (T2)  after  maximal  exercise
test. Comparison  of  T1  versus  T0  and  T2  versus  T0.
T0  T1  T1  vs  T0
p
T2  T2  vs  T0
p
IFNg  0.16  (0.04--1.57)  0.19  (0.06--0.95)  1.000b 0.15  (0.05--1.17)  0.739a
IL1b  15.46  (6.42--266.69)  19.38  (7.39--268.48)  0.383b 23.15  (5.63--250.58)  0.664b
IL6  0.33  (0.11--2.81)  0.51  (0.23--2.67)  0.189b 0.59  (0.10--2.05)  0.815b
IL8  1.82  (0.97--69.57)  4.70  (1.87--43.26)  0.189b 2.07  (0.94--43.37)  0.664b
TNFa  2.99  (2.55--47.00)  3.36  (2.25--29.61)  1.000b 3.42  (2.51--38.21)  0.383b
TGFb  199.71  (64.86--5462.36)  224.38  (63.91--4456.02)  0.383b 373.45  (75.18--5250.38)  0.078b
iNOS  0.03  (0.01--0.29) 0.04  (0.01--0.60) 0.791b 0.04  (0.01--0.31)  0.398a
a Exact Wilcoxon Signed ranks test.
b Sign test.
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‘Laboratory  results
In  the  ﬁrst  10  patients  studied,  we  did  not  ﬁnd  a  statis-
tically  signiﬁcant  difference  between  C0  and  T0,  the  two
time  points  of  baseline  resting  condition  (Annex-Table  2a).
The  characteristics  of  these  ﬁrst  ten  patients  entering  the
study  were  similar  to  all  group  characteristics:  6  men  (60%),
4  women  (40%),  mean  age  of  63.4  (SD:  6.9)  years  old
(ranging  from  56  to  79  years),  mean  post-bronchodilator
FEV1%predicted  44.5%  (SD:  23.6)  (R:  21--85%),  mean  BMI
24.8  kg  m−2 (SD:  4.3)  (R:  19--31  kg  m−2),  mean  69.9  pack-
years  (SD:  20.9)  (R:  45--100  pack-years).
In the  entire  sample,  there  was  no  statistically  signiﬁcant
difference  between  inﬂammatory  expression  at  rest  and  at
1  h  and  24  h  after  the  maximal  exercise  test  (Table  2).
Looking  at  associations  between  patients’  characteris-
tics  and  inﬂammation,  the  only  evidence  of  an  association
was  found  between  BMI  and  inﬂammatory  expression  at  all
time  points.  As  presented  in  Fig.  2,  a  slightly  inverse  asso-
ciation  occurs  with  low  BMI  (values  under  20  kg  m−2; n  =  3)
for  inﬂammatory  genes  mRNA  IL1b,  IL6,  TNFa,  TGFb  and
iNOS.  Moreover,  a  more  pronounced  positive  association  was
found  for  obese  patients  (BMI  above  30  kg  m−2;  n  =  4)  for  all
inﬂammatory  mRNA  genes  tested,  at  all  time  points.  No  cor-
relation  coefﬁcient  estimates  with  corresponding  p  values
were  reported  because  only  three  patients  were  malnour-
ished  and  four  patients  were  obese.
We  found  no  associations  between  inﬂammatory  expres-
sion  and  all  other  patients’  characteristics  and  variables,
including  demographics,  symptoms/health  status,  comor-
bidities  and  physiologic  parameters  (data  not  shown).
Due  to  the  previously  reported  potential  inﬂuence  of  car-
diovascular  comorbidity  in  the  inﬂammatory  expression  of
COPD  patients,29 we  looked  for  the  association  between
this  variable  and  inﬂammatory  gene  expression.  Higher
T1-T0  and/or  T2-T0  differences  were  found  (sometimes  with
statistical  signiﬁcance)  for  patients  without  cardiovascular
comorbidity  (Annex-Table  3a).
DiscussionIn  our  COPD  patient  sample,  real-time  polymerase  chain
reaction  of  the  target  mRNA  inﬂammatory  genes  did  not
show  increased  inﬂammation  either  at  rest  or  after  a
p
s
a
caximum  exercise  test.  When  looking  at  the  inﬂammatory
xpression  measured  in  resting  samples  on  two  consecutive
ays  (control  group),  there  were  also  no  statistical  differ-
nces  between  the  two  time  points,  which  might  reﬂect
tability  at  rest  mRNA  parameters.
Persistent  systemic  inﬂammation  is  not  a  universal  ﬁnd-
ng  in  patients  with  COPD.  ECLIPSE  study  recently  showed
hat  in  1755  COPD  patients,  about  30%  do  not  have  systemic
nﬂammation,  and  only  a  minority  (16%)  have  persistent
nﬂammation  during  1  year  follow  up.5
Although  we  expected  a  signiﬁcantly  different  mRNA
nﬂammatory  expression  at  1  and  at  24  h  after  maximal  exer-
ise,  in  line  with  other  authors,  such  as  Van  Helvoort  et  al.,15
ho  demonstrated  that  COPD  patients,  when  compared  to
ealthy  subjects,  are  exposed  to  systemic  inﬂammation  that
s  intensiﬁed  by  exhaustive  exercise,  we  did  not  ﬁnd  a
igniﬁcantly  different  mRNA  inﬂammatory  expression  after
hort-term  exercise.
However,  in  the  subgroups  of  malnourished  and  obese
OPD  patients,  we  found  opposite  associations  with  mRNA
nﬂammatory  expression.  When  considering  malnourished
atients,  mRNA  levels  of  iNOS,  IL6,  IL1b,  TNFa,  and  TGFb1
howed  a  tendency  to  decrease  with  increasing  BMI  values
oward  normal.  Conversely,  overweight  and  obese  patients
howed  higher  mRNA  levels  of  TNFa,  IFNg,  IL1b,  IL8,  TGFb1,
NOS  and  IL6  as  their  BMI  increasing  above  normal  values.
hen  considering  all  sample  data,  higher  mRNA  values  of
he  malnourished  on  one  side,  and  overweight  and  obese
atients  on  the  other,  shown  graphically  in  Fig.  2, might  be
lurred  by  the  lower  mRNA  values  of  normal  weight  patients.
his  could  explain  the  absence  of  a  signiﬁcant  association
f  inﬂammation  and  exercise  when  taking  into  account  the
edian  values  of  all  sample  data.
ECLIPSE  study  also  evidenced  high  BMI  as  one  of  the  inde-
endent  risk  factors  for  persistent  inﬂammation,  both  at
aseline  and  at  one  year  of  follow-up.5 This  association
as  not  evident  for  fat  free  mass  index,  which  suggests
n  important  role  for  adipose  tissue  in  systemic  inﬂam-
ation.  Garcia-Aymerich  and  colleagues30 also  identiﬁed  a
‘systemic’’  COPD  subtype  characterized  by  a  higher  pro-
ortion  of  obesity  in  342  COPD  patients  with  a signiﬁcant
ystemic  inﬂammation;  this  pattern  was  maintained  through
 4  years’  follow-up  period.  In  the  study  of  Tamakoshi  and
olleagues,  an  acute  phase  response  evidenced  by  serum
320  F.  Rodrigues  et  al.
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Figure  2  Association  between  inﬂammatory  biomarkers  at  rest  (T0)  and  at  1  h  (T1)  and  24  h  (T2)  after  maximal  exercise  test  and
body mass  index.  A  Lowess  was  ﬁtted  to  the  data.  Lowess  --  locally  weighted  scatterplot  smoother.
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levels  of  C-reactive  protein  increased  in  obesity  and  was
associated  with  insulin  resistance.31
Most  of  the  scientiﬁc  evidence  has  previously  shown  that
peripheral  muscle  atrophy  and  cachexia  are  associated  with
systemic  inﬂammation  in  patients  with  COPD,  when  com-
pared  to  patients  with  no  muscle  wasting.32,33 In  the  same
way,  in  our  study,  malnutrition  was  also  associated  with
higher  expression  on  mRNA  genes  iNOS,  IL6,  IL1b  and  TGFb1,
but  to  a  lesser  extent,  and  in  the  opposite  direction,  when
compared  to  what  happened  in  patients  with  higher  BMI.
Inﬂammation  in  COPD  has  been  associated  with  a
worse  prognosis.34 In  the  ECLIPSE  study,  persistent  inﬂamed
patients  had  signiﬁcantly  increased  all-cause  mortality
and  exacerbation  frequency  compared  with  non-inﬂamed
patients.5 In  our  study,  8  patients  were  deceased  after  4
years  (38%),  of  whom,  4  (50%)  were  obese  or  overweight,
and  3  (37.5%)  were  malnourished.  Only  one  patient  who  died
had  had  a  normal  BMI  at  baseline  (data  not  shown).
Cardiovascular  disease  is  the  most  prevalent  comorbidity
in  COPD,35--37 and  it  has  previously  been  associated  with  sys-
temic  inﬂammation  (elevated  C-reactive  protein)  in  patients
with  COPD.29 However,  although  prevalent  (71%),  cardiovas-
cular  disease  was  not  associated  with  higher  inﬂammatory
expression  for  all  genes  studied.  These  results  do  not  seem
to  be  inﬂuenced  by  different  exercise  protocols  involved,
as  both  patients  with  and  without  cardiovascular  comor-
bidities  exercised  on  the  same  ergometers,  used  the  same
protocols  and  exercised  to  their  maximal  tolerance.  Patients
without  cardiovascular  comorbidity  achieved  higher  work
load  in  cycle  ergometer,  but  lower  workload  on  the  tread-
mill.  However,  assuming  that  the  sample  studied  is  too  small
to  be  representative,  a  deﬁnite  conclusion  of  cardiovascu-
lar  comorbidity  not  being  associated  with  higher  levels  of
inﬂammation  after  exercise  in  COPD  patients  can  only  be
established  with  larger  samples.
There  is  still  an  unmet  need  to  characterize  differ-
ent  COPD  phenotypes  that  might  beneﬁt  from  different
treatment  approaches  and  respective  outcomes.  Inhaled
corticosteroids,  as  an  example,  have  limited  efﬁcacy  in  the
reduction  of  systemic  inﬂammation  in  COPD.38 On  the  other
hand,  a  non-pharmacological  approach,  such  as  pulmonary
rehabilitation  with  exercise  training,  has  been  proven  to
improve  exercise  tolerance,  while  modifying  body  compo-
sition  toward  a  higher  fat-free  mass,  improving  muscle
function,  and,  as  evidenced  by  some  studies,  it  might  also
attenuate  systemic  inﬂammation.6
The  present  study  has  a  number  of  limitations  that  need
to  be  addressed.  A  small  sample  size  was  not  able  to  rule
out  the  presence  of  an  increased  systemic  inﬂammation.
Although  small,  this  sample  size  was  enough  to  show  graph-
ically  an  association  between  BMI  and  inﬂammation.  It  is  an
exploratory  study  and  longitudinal  studies  with  larger  sam-
ples  are  needed  to  conﬁrm  this  association.  Studies  designed
to  deﬁnitely  exclude  OSA  or  OHS  as  confounding  in  obese
patients  are  also  required.
Another  limitation  might  be  the  fact  that  levels  of  plasma
proteins  and  related  mRNA  precursors  are  sometimes  not
coincident.39,40 Cytokine  protein  production  is  strictly  regu-
lated  at  multiple  steps,  including  transcription  (mRNA  chain
generation)  and  translation  (protein  synthesis  from  RNA).
Plasma  cytokine  expression  will  depend  on  the  efﬁciency  of
translation  of  mRNA  into  useful  proteins.321
Although  our  study  suggested  an  association  between
besity  and  several  inﬂammatory  genes,  and  other  authors
lso  evidenced  RT-PCR  as  an  attractive  method  of  studying
he  gene  expression  of  cytokines  in  whole  blood,41 an  addi-
ional  study  should  be  carried  out  to  confront  mRNA  genes
nd  the  corresponding  plasma  proteins.
onclusions
his  preliminary  study  evidenced  an  association  between
MI  (malnutrition  and  obesity)  and  the  levels  of  inﬂam-
atory  mRNA  cytokine  precursors,  suggesting  not  only
alnourishment,  but  also  obesity  as  potential  links  between
OPD  and  systemic  inﬂammation.
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